AI Analysis
AI-generated analysis. Always verify with the original filing.
Genmab A/S held its Annual General Meeting on March 19, 2026, approving the 2025 Annual Report and Compensation Report, granting discharge to the Board of Directors and Executive Management, and carrying forward USD 963 million profit to retained earnings. Six board members were re-elected, Deloitte was reappointed as auditor, and share capital was reduced by DKK 1,900,000 via treasury share cancellation.
Key Takeaways
12025 Annual Report approved
2USD 963 million profit for 2025 carried forward to retained earnings
3Six board members re-elected for one-year term: Deirdre P. Connelly, Pernille Erenbjerg, Rolf Hoffmann, Elizabeth O’Farrell, Paolo Paoletti, Anders Gersel Pedersen
4Deloitte Statsautoriseret Revisionspartnerselskab re-elected as auditor
5Share capital reduced by DKK 1,900,000 through cancellation of treasury shares
62026 Board remuneration proposal withdrawn